Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Recurrence 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

venetoclax 30obinutuzumab 22acalabrutinib 20Specimen Handling 19ibrutinib 16Cyclophosphamide 15Biopsy 15pirtobrutinib 14zanubrutinib 12fludarabine 12Rituximab 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 5Stem Cell Transplantation 4Blood Component Removal 4ARQ531 4idelalisib 3fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3tocilizumab 2polatuzumab vedotin 2Watchful Waiting 2Sirolimus 2Prednisone 2Pneumococcal Vaccines 2Lisaftoclax 2Leukapheresis 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × polatuzumab vedotin × Clear all
NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Dana-Farber Cancer Institute

Phase 2 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Weill Medical College of Cornell University

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡